Viewing Study NCT03355157

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:51 PM
Ignite Modification Date: 2026-01-05 @ 7:06 PM
Study NCT ID: NCT03355157
Status: COMPLETED
Last Update Posted: 2024-10-01
First Post: 2017-11-22
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
Sponsor: GBG Forschungs GmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Palbociclib View
None Endocrine Therapy View
None Chemotherapy View
None Real world setting View
None Electronic patient-reported outcome View
None Daily Monitoring Treatment Impact View
None Health care utilization (call tracking, geofencing) View